In vitro activity of tigecycline against Gram-positive cocci: A multicentre study in Greece

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 5, 2008, Pages 1158-1160

  Malli, E ^a   Spiliopoulou, I ^b   Kolonitsiou, F ^b   Neocleous, Ch ^c   Klapsa, D ^c   Pantelidi, K ^c   Panopoulou, M ^d   Grapsa, S ^d   Alepopoulou, E ^d   Neonakis, I ^e   Alexiou Daniel, S ^f   Bakola, D ^g   Koutsia Carouzou, C ^h   Malamou Lada, H ^h   Zerva, L ⁱ   Vlahaki, E ^j   Kartali Ktenidou, S ^d   Anastassiou, E ^b   Petinaki, E ^a,c  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c Institute of BioMedical Research and Science   (Greece)

^d DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^f AHEPA UNIVERSITY HOSPITAL   (Greece)

^g General Hospital of Lamia   (Greece)

^h IASO GENERAL HOSPITAL   (Greece)

ⁱ NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^j General Hospital of Volos   (Greece)

more..

Author keywords

Enterococci; Pneumococci; Resistance; Staphylococci; Streptococci

Indexed keywords

AMPICILLIN; CEFOXITIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LINEZOLID; METICILLIN; MINOCYCLINE; OXACILLIN; PENICILLIN G; TEICOPLANIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM ISOLATE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE COCCI; GREECE; IN VITRO STUDY; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; GREECE; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 54549123672     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn344     Document Type: Letter

References (6)

1. Livermore DM. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611-4.
2. Tenover FC, Arbeit RD, Goering RV et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995; 33 2233-9.
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
4. Milatovic D, Schmitz FJ, Verhoef J et al. Activities of the glycylcycline tigecycline (GAR-936) against 1924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003; 47: 400-4.
5. Hoban DJ, Bouchillon SK, Johnson BM et al. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005; 52: 215-27.
6. Werner G, Gfrorer S, Fleige C et al. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 2008; 61: 1182-3.